Investigational drug · Phase 2
TTI-0102
Also called: cysteamine-pantetheine disulfide
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Nephropathic Cystinosis, Cystinosis, MELAS Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "TTI-0102"
First trial start
2025
May 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TTI-0102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nephropathic Cystinosis
- Cystinosis
- MELAS Syndrome
- Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "TTI-0102" as an intervention, largest first.
- A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)Not yet recruiting
Thiogenesis Therapeutics, Inc.Industry
NCT06990984 · 18 participants (planned) · Start Oct 2026 · Primary completion Jun 2027
Drug: TTI-0102: cysteamine-pantetheine disulfide; D-Mannitol · For: Leigh Syndrome
Thiogenesis Therapeutics, Inc.Industry
NCT06644534 · 9 participants · Start May 12, 2025 · Primary completion Jan 12, 2026
Drug: TTI-0102; Placebo · For: MELAS Syndrome; Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
Sites: Angers, France; Nijmegen, Netherlands
- Pilot Study of TTI-0102 in CystinosisNot yet recruiting
Thiogenesis Therapeutics, Inc.Industry
NCT07837726 · 6 participants (planned) · Start Oct 2026 · Primary completion Dec 2026
Drug: TTI-0102 (cysteamine-pantetheine disulfide) · For: Nephropathic Cystinosis; Cystinosis
- TTI-0102 for Veterans With TBIWithdrawn
VA Office of Research and DevelopmentFederal agency
NCT04262895 · 0 participants · Start Oct 1, 2021 · Primary completion Oct 15, 2021
Drug: TTI-0102; Placebo · For: Mild to Moderate TBI; Posttraumatic Stress Disorder
Sites: San Diego, California
Thiogenesis Therapeutics, Inc.Industry
NCT05212662 · 0 participants · Start Sep 27, 2024 · Primary completion Sep 27, 2024
Drug: TTI-0102; Placebo · For: COVID-19; COVID-19 Acute Respiratory Distress Syndrome
Newest research
PubMed records naming it or its code names, newest first.
- Mitochondrial DNA A3243G variant-associated MELAS: Recent advances in clinical trials, therapeutic interventions, and disease-modifying strategies.
Chu KY · Intractable Rare Dis Res 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.